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ABSTRACT
Background HIV, diabetes and hypertension have a 
high disease burden in sub- Saharan Africa. Healthcare 
is organised in separate clinics, which may be 
inefficient. In a cohort study, we evaluated integrated 
management of these conditions from a single chronic 
care clinic.
Objectives To determined the feasibility and 
acceptability of integrated management of chronic 
conditions in terms of retention in care and clinical 
indicators.
Design and setting Prospective cohort study comprising 
patients attending 10 health facilities offering primary care 
in Dar es Salaam and Kampala.
Intervention Clinics within health facilities were set up to 
provide integrated care. Patients with either HIV, diabetes 
or hypertension had the same waiting areas, the same 
pharmacy, were seen by the same clinical staff, had similar 
provision of adherence counselling and tracking if they 
failed to attend appointments.
Primary outcome measures Retention in care, plasma 
viral load.
Findings Between 5 August 2018 and 21 May 2019, 
2640 patients were screened of whom 2273 (86%) 
were enrolled into integrated care (832 with HIV 
infection, 313 with diabetes, 546 with hypertension and 
582 with multiple conditions). They were followed up 
to 30 January 2020. Overall, 1615 (71.1%)/2273 were 
female and 1689 (74.5%)/2266 had been in care for 6 
months or more. The proportions of people retained in 
care were 686/832 (82.5%, 95% CI: 79.9% to 85.1%) 
among those with HIV infection, 266/313 (85.0%, 
95% CI: 81.1% to 89.0%) among those with diabetes, 
430/546 (78.8%, 95% CI: 75.4% to 82.3%) among 
those with hypertension and 529/582 (90.9%, 95% CI: 
88.6 to 93.3) among those with multimorbidity. Among 
those with HIV infection, the proportion with plasma 
viral load <100 copies/mL was 423(88.5%)/478.
Conclusion Integrated management of chronic diseases 
is a feasible strategy for the control of HIV, diabetes 
and hypertension in Africa and needs evaluation in a 
comparative study.
BACKGROUND
The prevalence of diabetes and hypertension 
has risen sharply in Africa, where these condi-
tions are now responsible for around 2 million 
premature adult deaths annually.1–6 There are 
effective treatments for diabetes and hyper-
tension, but only 10%–20% of persons living 
with these conditions are thought to be in 
regular care,1 7 8 largely because service provi-
sion is limited.9–11 Identifying approaches 
to increase access to health services for the 
management of diabetes and hypertension 
for populations in Africa represents one of 
the greatest public health challenges of our 
time.
Health services in most African countries 
are generally designed for dealing with acute 
infections and experience of chronic care 
management is limited,12 except for HIV 
infection which, like other chronic diseases, 
requires life- long management. In Eastern 
and Southern Africa 83% of people who 
know they have HIV infection are in regular 
care, with 90% of these virally suppressed,13 
compared with a retention rate of about 
50% a decade or so ago.14 15 HIV- associated 
mortality has declined from over 2 million a 
Strengths and limitations of this study
 ► This study is a multisite and is the largest ever con-
ducted on integrating chronic care for HIV, diabetes 
and management in Africa.
 ► Study was done in close to real- life health ser-
vice conditions and so findings are likely to be 
generalisable.
 ► The study was intended to determine feasibility and 
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year to less than half a million a year13 and hypertension 
and diabetes will need to achieve similar levels of reten-
tion and disease control to achieve the large declines in 
mortality needed to meet the Sustainable Development 
Goals.16
One reason why HIV services have been successful 
might be because they have been organised in stand- 
alone clinics in most African countries from shortly 
after the time that effective antiretroviral drugs became 
available. People living with HIV infection are managed 
in separate primary care clinics, with separate drug and 
diagnostic procurement channels and a separate funding 
stream. Now that the burden of other chronic conditions 
is a rapidly increasing public health problem, how should 
African health systems organise their services?
Managing multiple chronic conditions in the same 
clinics could reduce the duplication of healthcare 
resources and, crucially, could enable the learning 
acquired by HIV treatment programmes to be applied to 
the control of other chronic conditions. However, there is 
little evidence to support this in public health facilities.17 18 
Integrated management could deter people with diabetes 
and hypertension in seeking care because of the stigma 
associated with HIV infection. There is also a danger, that 
expanding the focus of healthcare provision in relatively 
weak health systems, could put at risk the gains achieved 
by HIV control programmes. In Tanzania and Uganda, 
working in close collaboration with policymakers and 
senior disease control managers, we conducted a cohort 
study of the integrated care for HIV infection, diabetes 
and hypertension and evaluated its feasibility and accept-
ability in terms of retention in care and clinical indicators 
including control of blood pressure and fasting plasma 
glucose.
METHODS
Study design and setting
We conducted a prospective cohort study, known as the 
MOCCA (Management of Chronic Conditions in Africa) 
study. We provided integrated care at 10 health facilities 
that were offering primary healthcare services, 5 in the 
Dar es Salaam region in Tanzania and 5 in and around 
Kampala, Uganda and followed up a cohort of partici-
pants over time to determine the feasibility and accept-
ability of this approach in terms of retention in care and 
clinical indicators. Online supplemental appendix 1 
describes the health facilities included.
The facilities were serving largely urban and periurban 
populations and chosen purposely. Eight were govern-
ment run and two were run by non- government organ-
isations. They ranged from regional hospitals through 
to smaller health centres and dispensaries.19 20 The 
larger facilities operated stand- alone separate clinics for 
diabetes and hypertension, while in the small facilities, 
patients with diabetes or hypertension were usually seen 
in the outpatient clinic. Each facility had a HIV clinic run 
separately from the rest of the clinical services. Patients 
attending HIV services had their own reception and 
waiting area, were seen by dedicated clinical staff and 
had a separate pharmacy. Medical records, track and 
trace procedures and appointments also all differed from 
systems employed in other clinics in the facility.
What was integrated care?
Integration involved the formation of a single clinic for 
the management of patients with HIV infection, diabetes 
or hypertension or combinations of these conditions. 
All patients were seen by the same clinical staff. They 
shared a single reception, waiting areas and pharmacy. 
For patients with diabetes or hypertension, systems for 
tracking and follow- up of patients, recording of clinical 
notes, counselling, appointments and registrations were 
mostly set up from new and aligned with those available 
for people living with HIV, such that all patients were 
managed in a similar way regardless of their condition.
How was integrated care implemented?
In Uganda, the first person received integrated care on 
5 October 2018 and recruitment finished on 5 April 
2019. The final follow- up was on 20 December 2019. In 
Tanzania, the first person received integrated care on 20 
February 2019. Recruitment finished on 23rd June 2019. 
The final follow- up was on 30 January 2020.
We conducted assessments of each facility using a modi-
fied WHO Service Availability and Readiness Assessment 
tool and reviewed routine data from the Health Manage-
ment Information Systems (District Health Information 
System 2). This provided us with knowledge on the clin-
ical infrastructure, availability of medicines, frequency 
and nature of patient attendance for assessments.
The integrated care clinic was set up to run separately 
as a stand- alone clinic at each facility so that patients who 
did not want integrated care would be able to continue 
with usual clinics. Organisation of the integrated care 
clinic, including the frequency of clinic days, was done by 
health facility managers. Where possible the integrated 
clinic was run on a different day from the HIV and hyper-
tension or diabetes stand- alone clinics. In those facilities 
where this was not possible, it was run in a separate room 
away from the main stand- alone clinics. The integrated 
clinic was held initially on 1 day a week at all facilities 
and later increased to 2 days a week as the numbers of 
recruited participants increased. Clinical management 
was done by healthcare staff employed by the facilities 
and in accordance with local clinical practice and national 
guidelines.
The healthcare staff received refresher training in all 
three chronic health conditions to ensure a common 
level of understanding of clinical management. Certi-
fied national trainers conducted training in both coun-
tries. The training comprised a combination of 2 days 
of classroom sessions and on- the- job training. The 
doctors specialised in HIV and in non- communicable 
disease management conducted joint clinics for up to 1 
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conditions. Classroom training included role play of 
different scenarios.
Counselling was generally not available for diabetes 
and hypertension management in either country prior to 
the study but was available routinely for patients with HIV 
infection. We therefore provided training to nurses and 
counsellors on diabetes and hypertension, focused on the 
need for high treatment adherence to prevent complica-
tions. It comprised 1 day of classroom training followed 
by on- the- job training for up to 4 weeks, as done for clini-
cians, and mentorship.
Prior to the study, HIV clinics had a system of tracking 
patients who did not attend a scheduled appointment. 
This generally involved contacting patients by phone if 
they missed an appointment, to determine the reason for 
the missed appointment and to reschedule. Such prac-
tices were not in place for people with either diabetes 
or hypertension. Therefore, we extended the system of 
tracking patients to cover all three conditions.
All health facility staff received training on the 
protocol and research methods. This was approximately 
1 day of classroom training, followed by on- the- job 
training.
Data collection
At each clinic, the research team employed one data 
clerk and one research nurse to inform patients about 
the research, collect research data and take informed 
consent. In addition, small amounts of salary (salary top- 
ups) were provided to selected facility staff working with 
study participants and to the head nurse responsible for 
the facility operations including overseeing the logistical 
set up of integrated care activities. Research staff worked 
alongside the health facility staff.
Selection of participants
In each disease- specific clinic a health talk was given 
to introduce the study. The number of patients with 
diabetes or with multiple conditions was very few. There-
fore, all persons presenting with diabetes or with two or 
all three of our target conditions were invited to join the 
study. Both existing and newly diagnosed patients were 
enrolled. In the larger facilities (n=3, all in Tanzania), 
the number of people in care with HIV infection or with 
hypertension was large and so we sampled systematically 
(usually every 20th patient) until the clinic ended for the 
day. In the remaining clinics, where patient load was lower 
and it was difficult to ascertain the order that patients had 
come to the facility, we enrolled patients who approached 
study staff to find out more, or clinicians approached 
patients and invited them to be screened for the study. 
On most clinic days, patients who had recently arrived at 
the facility came forward for enrolment, and those who 
had nearly completed their consultations for the day and 
were close to leaving the facility for home, were reluctant 
to come forward.
Provision of medicines for hypertension and diabetes
Before the study started, we recognised that supply of 
medicines for diabetes and hypertension was erratic in 
both countries. In Uganda, medicines for these condi-
tions were normally provided free but shortages were 
common. In Tanzania, most patients were required to 
purchase medicines, and some had health insurance. 
We have discussed elsewhere the ethical challenges of 
conducting research of this kind in situations of limited 
medicines supply.21
To ensure a reliable supply of drugs, we purchased 
back- up supplies of basic drugs for diabetes and hyper-
tension in both Tanzania and Uganda and supplemented 
patient supplies when the health service stock ran out. 
The medicines supplied were predominantly first- line 
drugs and differed between countries depending on what 
was needed.
Due to the limited supply of medicines for diabetes 
and hypertension in Uganda, patients at one of the study 
facilities had organised themselves into a group that met 
and pooled funds on a monthly basis. These funds were 
used to purchase the medicines when the health facility 
ran out of stock. At this facility, we offered minimal buffer 
supplies compared with other facilities.
Measurements
Retention was assessed through routine attendance at 
clinics. Patients who failed to attend an appointment 
were phoned to establish reasons for not attending and 
to reschedule. Three attempts were made to contact the 
patient by phone in the month following non- attendance 
at an appointment. A patient was regarded as lost to 
follow- up if they had not attended an appointment within 
the last 6 months.
Blood pressure was measured using the Omron M6 
comfort (OMRON Healthcare, Japan) in Uganda and 
in three of the facilities in Tanzania; Suresign SLD3- 107 
(CIGA Healthcare Ltd, UK) was used in the remaining 
facilities. We measured blood pressure at three time 
points in the sitting position, 5 min apart, and took the 
average of the three readings as the pressure. Hyperten-
sion was defined as a systolic pressure ≥140 mm Hg and/
or a diastolic pressure ≥90 mm Hg and/or use of antihy-
pertensive medication.
Plasma viral load testing was done by the Central 
Public Health laboratories in Tanzania and Uganda using 
the Cobas 8800 system (Roche). In Uganda, if the viral 
load result from the central laboratory was not available 
or was more than 6 months old, a test was done at the 
MRC/UVRI/LSHTM Uganda laboratory using Cobas 
Ampliprep. In both countries glycated haemoglobin 
(HbA1c) testing was not routinely available in the public 
health system, and this was done by the study. In Uganda, 
HbA1c was tested by Cobas 6000 (Roche, Switzerland) 
at the MRC/UVRI/LSHTM Uganda laboratory, and in 
Tanzania at the Shree Hindu Mandal Hospital laboratory 
using a Siemens DCA Vantage (Siemens Healthcare Diag-
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a point of care test in Tanzania (GlucoDr. Auto AGM- 4000 
and all Medicus Co, Republic of Korea) and in Uganda 
Contour Plus (Bayer, Germany).
In Tanzania, weight and height were measured using 
SECA RGZ- 160 (SECA, GmbH & Co, Germany). In 
Uganda, we used an ADE spring scale (1–150 kg) for 
weight measurement and SECA 213 portable stadiom-
eter (SECA, German) for height measurement. Weight 
and height were measured to the nearest ±0.1 kg and ±0.1 
cm, respectively, and body mass index was calculated as 
weight/height2 (kg/m2).
Patient and public involvement
The concept of integrated care was developed in partner-
ship with senior policymakers. In each country, we held 
planning meetings with the Ministry of Health and non- 
governmental partners at national and local level, with 
senior clinicians and hospital managers and with patient 
leaders and community representatives. National steering 
committees were formed, comprising representatives 
from these stakeholders together with the researchers 
and these committees contributed to the research strategy 
and guided its implementation. We also formed an inter-
national steering committee, that included four senior 
researchers and four independent researchers, which 
had oversight of the whole programme. We also held 
investigator meetings involving all of the partners and 
these included patient representatives and policymakers.
Statistical analysis
The measure of retention used was defined as number 
in care at study end, calculated as the number enrolled 
into integrated care minus any deaths, losses to- follow- up, 
transfers away from the health facility and withdrawals of 
consent.
Categorical variables were summarised using frequen-
cies and proportions and compared using χ2 tests. Contin-
uous variables were summarised using means or medians 
and compared by a t- test or a Wilcoxon test, as appro-
priate. Generalised estimating equations were used to 
account for clustering at the health facility level. Kaplan- 
Meier curves and Cox regression with frailties (to adjust 
for clustering) were used to analyse retention times. The 
time was calculated as number of months from first atten-
dance at the integrated clinic to the earliest of the end of 
the study, loss to follow- up, death, withdrawal or transfer 
out. The analysis was done using STATA V.15.
RESULTS
Figure 1 shows the consort chart. Of 2640 patients assessed 
for eligibility, 102 (3.9%) did not meet eligibility criteria 
(34 were sick and requiring urgent medical attention or 
hospital admission, 50 were planning to move out of the 
area, 13 were pregnant and receiving care from antenatal 
care services, 5 other reasons), 19 (0.7%) declined and 
gave no reason, 51 (1.9%) wanted more time to decide 
(mostly to discuss with their family), 34 (1.3%) were 
approached just as they had finished consultation and 
were leaving the clinic and 18 (0.7%) gave other reasons 
(mostly that they needed to be in specialist care).
Thus, of all those initially assessed for eligibility 91.5% 
(2416/2640) were invited to join integrated care. This 
invitation was given at their current clinics and they were 
asked to return at their next visit to the integrated care 
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clinic. Six per cent (143/2416) did not return and thus 
2273 (86.1%)/2640 were enrolled into integrated care, 
927 in Tanzania and 1346 in Uganda.
Table 1 shows the characteristics of the participants at 
the start of integrated care, for each clinical condition. 
Overall, 74.5% (1689/2266) reported that they had 
been in care for 6 months or more prior to the start of 
the study. For people with multiple conditions, previous 
time in care was substantially greater than for those with 
single conditions. Overall, 71.1% (1615/2273) of those 
included in the study were female.
Median age varied substantially between the different 
conditions, with that for those living with HIV infection 
being more than 10 years younger than participants in 
the other groups (p=0.0001, Kruskal- Wallis test). Obesity 
was more common among participants with diabetes, 
hypertension or multimorbidity than among participants 
with HIV (504/1441 (35.0%) vs 116/832 (13.9%), risk 
ratio adjusted for clustering: 2.50, 95% CI: 1.88 to 3.31, 
p<0.001). It was also substantially higher in women than 
in men (554/1615 (34.3%) vs 66/658 (10.0%), adjusted 
risk ratio: 3.40, 95% CI: 2.63 to 4.41, p<0.001).
Table 2 shows the biomedical indicators as measured at 
baseline on the day of integration or within the previous 
6 months. The majority did not reach target blood pres-
sure and glycaemia control levels, whether they had a 
single condition or multimorbidity. When participants 
who reported that they had been in care for less than 6 
months (ie, patients who had newly started therapy) were 
excluded, 509 (57.7%)/882 of those with hypertension 
had a blood pressure ≥140/90 mm Hg, 355/508 (69.9%) 
of those with diabetes had a fasting blood glucose ≥7.0 
mmol/L and 72 (16.4%)/438 of those with HIV infection 
had a plasma viral load ≥100 copies/mL.
The proportions alive and retained in care were high 
among all participants (table 3). The overall proportion 
alive and in care among participants with a single condi-
tion was 1382/1691 (81.7%, 95% CI: 79.9% to 83.6%), 
which did not differ significantly from the proportion 
with multimorbidity (adjusted risk ratio: 0.91, 95% CI: 
0.82 to 1.00, p=0.061).
Figure 2 shows the survival probability curves of being 
alive and in care over time. After adjusting for clustering, 
the probability (95% CI) of being retained and alive in 
care at 12 months was 0.74 (0.66–0.80) among partici-
pants with HIV alone, 0.74 (0.66–0.81) among those with 
diabetes alone, 0.70 (0.64–0.76) among those with hyper-
tension alone and 0.84 (0.79–0.88) among those with 
multimorbidity (p=0.008).
Table 4 shows the biomedical indicators of partici-
pants at the final follow- up. The proportions of patients 
living with HIV infection with viral suppression were 
Table 1 Baseline characteristics of patients studied
Number recruited into integrated care HIV only Diabetes only Hypertension only Multiple conditions
Total 832 313 546 582
In Tanzania 352 164 160 251
In Uganda 480 149 386 331
Type of health facility
  Large public facilities 235 81 153 184
  Small public facilities 409 155 282 217
  NGO facilities 188 77 111 181
Time in care prior to enrolment, number (%)*
  <6 months 310 (37.4) 63 (20.3) 165 (30.3) 39 (6.7)
  6–11 months 41 (5.0) 28 (9.0) 42 (7.7) 22 (3.8)
  12–59 months 167 (20.1) 98 (31.6) 172 (31.6) 135 (23.2)
  ≥60 months 311 (37.5) 121 (39.0) 166 (30.5) 386 (66.3)
  Median (range) months in care 26.1 (0.0–343.4) 38.3 (0.0–431.6) 26.4 (0.0–566.2) 106 (0.0–534.8)
  Female, number (%) 571 (68.6) 208 (66.5) 399 (73.1) 437 (75.1)
  Median age, (range) 38 (18–78) 49 (19–77) 56 (27–86) 55 (21–85)
BMI, number (%)
  <25 531 (63.8) 118 (37.7) 175 (32.1) 163 (28.0)
  25–29.9 185 (22.2) 98 (31.3) 181 (33.2) 202 (34.7)
  ≥30 116 (13.9) 97 (31.0) 190 (34.8) 217 (37.3)
  Median BMI (range) in men 21.1 (14.8–35.6) 24.3 (15.1–37.0) 25.1 (16.7–41.6) 26.0 (17.0–53.1)
  Median BMI (range) in women 24.4 (13.2–48.9) 28.5 (15.4–48.2) 28.8 (16.0–65.2) 28.8 (15.8–57.9)
*Missing for seven participants (three with HIV infection, three diabetes and one hypertension).
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high, but the proportions of those with hypertension 
achieving blood pressure less than 140/90 mm Hg and 
those with diabetes achieving glycaemia <7 mmol/L 
were substantially lower. However, blood pressure, 
fasting glucose and plasma viral load were all better 
controlled at study end than at baseline (table 5), even 
when participants who had been in care for less than 6 
months, and would have been newly started on therapy 
were excluded. After adjusting for clustering, among 
patients with HIV, the proportion (95% CI) with plasma 
viral load of <100 copies/mL was 88.5% (85.7%–91.4%) 
and those with plasma viral load <1000 copies/mL was 
96.0% (94.3%–97.8%).
DISCUSSION
This study shows that integrating care for HIV infec-
tion, diabetes and hypertension achieved high levels 
of retention in care for people living with diabetes or 
hypertension in Africa. Crucially, this improvement 
did not appear to be at the expense of HIV control, 
as retention in all three groups of people with single 
conditions was similar, and the proportion with an HIV 
viral suppression of less than a 100 copies/mL was close 
to 90%.
Thus, our study suggests that an integrated approach 
could achieve excellent retention for diabetes and hyper-
tension in an integrated clinic, as has been achieved for 
Table 2 Biomedical indicators at baseline
Patients who have 
a single condition 
occurring alone
The condition occurs with 
other conditions, causing 
multimorbidity (only among 
those with the condition) Both combined
Among patients with hypertension
  Blood pressure (mm Hg), number (%) n=546 n=539 n=1085
  ≥140/90 342 (62.6) 327 (60.7) 669 (61.7)
  <140/90 204 (37.4) 212 (39.3) 416 (38.3)
  ≥180/120 42 (7.7) 64 (11.9) 106 (9.8)
  <180/120 504 (92.3) 475 (88.1) 979 (90.2)
  Systolic BP mm Hg, mean (range) 144.4 (83.0–257.7) 145.1 (68.7–271.0) 144.7 (68.7–271.0)
  Diastolic BP mm Hg, mean (range) 90.2 (43.3–163.0) 90.3 (54.7–167.3) 90.2 (43.3–167.3)
Among patients with diabetes
  Fasting glucose (mmol/L), number (%) n=228 n=281 n=509
  <6.1 34 (14.9) 62 (22.1) 96 (18.9)
  6.1–6.9 17 (7.5) 32 (11.4) 49 (9.6)
  ≥7.0 177 (77.6) 187 (66.6) 364 (71.5)
  Fasting glucose, mean (range) mmol/L 11.5 (2.9–29.3) 9.8 (2.3–28.2) 10.5 (2.3–29.3)
  HbA1c, number (%)* n=124 n=206 n=330
  <6.0% 4 (3.2) 25 (12.1) 29 (8.8)
  
  6.0%–6.4%
7 (5.7) 22 (10.7) 29 (8.8)
  ≥6.5% 113 (91.1) 159 (77.2) 272 (82.4)
  HbA1c, mean (range) in % 10.1 (4.8–16.9) 8.8 (4.8–16.5) 9.3 (4.8–16.9)
Among patients living with HIV
  HIV plasma viral load, number (%)* n=493 n=153 n=646
  <100 copies/mL 306 (62.1) 131 (85.6) 437 (67.7)
  100–999 copies/mL 68 (13.8) 14 (9.2) 82 (12.7)
  ≥1000 copies/mL 119 (24.1) 8 (5.2) 127 (19.7)
Note: blood pressure was measured at baseline by research staff among 1187 (99.9%)/1188 participants who were not known previously to 
be hypertensive. Of these, the proportion who were detected with a blood pressure of 140/90 mm Hg or higher was 80 (9.6%)/831 among 
those with HIV infection alone, 47 (15.0%)/313 among those with diabetes alone and 6 (14.0%)/43 among those with HIV infection and 
diabetes. Of note, among all HIV- infected participants, blood pressure was 180/120 mm Hg or higher among 45 (4.0%)/1126.
*Measured at any time within the previous 6 months. Overall for the proportion with plasma viral load <100 copies/mL, the 95% CI was 
64.1%, 71.4% and 80.3% (95% CI: 77.3% to 83.5%) had a plasma viral load <1000 copies/mL.
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people living with HIV infection where retention exceeds 
80% today, up from about 50% a decade or so ago.13–15
The retention rate for people with diabetes or hyperten-
sion observed in our study was higher than that published 
from some other studies, which involved studies of single 
diseases, including those where diagnostic and treatment 
services were enhanced and, for example, treatments 
were provided for free.22–24 In our study, we put in place 
basic measures to support participants with diabetes and 
hypertension including minimal access to basic medi-
cines, counselling and telephone reminders for those 
who missed appointments. However, these measures were 
no more than those available to people in care with HIV 
infection and no more than those available to people in 
research studies of hypertension and diabetes. No finan-
cial or other incentives were provided in our study and 
participants were managed by routine healthcare staff. 
Analysis of the costs of this package will be done sepa-
rately but generic medicines for diabetes and hyperten-
sion and associated monitoring costs are substantially less 
than those for HIV infection and so we anticipate that the 
model will be highly cost- effective.
In a large study in Malawi conducted by members of 
our team almost a decade ago, people identified with 
diabetes and hypertension in the community were 
referred into care with a dedicated medical officer and 
access to a free and reliable supply of medicines and diag-
nostics. However, at 12 months retention in care was 27%, 
suggesting that control of diabetes and hypertension when 
these conditions are identified through routine screening 
(ie, are asymptomatic) might be a challenge.23 25 A study 
from Kwazulu- Natal in South Africa reported similar find-
ings.26 However, other studies that provided a good level 
of care and that have involved patients who know they 
have diabetes and hypertension have also struggled to 
achieve good levels of retention.22
Why did our study achieve high retention? For people 
with multiple conditions, a huge advantage of integrated 
care is that they only need to attend one clinic appoint-
ment, but in our study retention was also high for people 
with single conditions. It is possible that when services 
were integrated and the lessons learnt in managing HIV 
infection with respect to counselling, treatment adher-
ence and the provision of a more streamlined service, 
were applied by healthcare staff to diabetes and hyper-
tension management, patients responded to the changes 
in service delivery. The mixing of patients with HIV infec-
tion with those living with diabetes and hypertension may 
also have led to the sharing of experiences of living with 
a long- term condition, which could have brought further 
benefit.
We knew that integration of services would involve 
expansion of care responsibilities of health facility staff, 
and feared that this would adversely impact HIV care 
outcomes.17 27 28 However, this did not happen. HIV 
viral suppression rates were high at enrolment and 
were slightly higher at the end of the study. There is an 
increasing body of literature on integrating screening, 
diagnosis and treatment for non- communicable diseases 
into established HIV services.17 29 30 As far as we are aware, 
ours is the first study to test integration of services fully 
so that any person with one or more of the three target 
conditions could be managed in one clinic.29 31
Table 3 Retention in integrated care and clinical outcomes according to condition





Number enrolled into integration 832 313 546 582
Median follow- up (interquartile range) 8.2 (6.9–10.4) 8.0 (6.9–9.4) 8.2 (6.9–10.1) 8.2 (7.2–9.8)
Retained in care to the end of the study, n% 
(95% CI)*
n.686
82.5 (79.9 to 85.1)
n.266
85.0 (81.1 to 89.0)
n.430
78.8 (75.4 to 82.3)
n.529
90.9 (88.6 to 93.3)
Rate per 100 person years (95% CI)* 75.0 (70.6 to 78.7) 77.7 (70.4 to 83.3) 69.9 (63.5 to 74.6) 87.1 (83.2 to 90.2)
Note: 85 persons were newly diagnosed with multiple conditions over the course of follow- up. Of participants with HIV alone, 5 were 
diagnosed with diabetes and 33 with hypertension. Of those with diabetes, 3 tested positive for HIV and 23 were diagnosed with 
hypertension. Of those with hypertension, 1 tested positive for HIV and 9 were diagnosed with diabetes. Eleven persons with dual conditions 
were diagnosed with a third condition.
*Adjusted for clustering at health facility level.
Figure 2 Kaplan- Meier curves showing probability 
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We had feared that stigma may put off patients with 
diabetes and hypertension from attending a joint service 
with patients living with HIV. However, none of the 
patients who declined to join cited stigma. It is possible 
that the 41 patients who declined without giving a reason 
or who deferred their decision, did so because of the 
stigma. Nonetheless, these numbers of refusals are rela-
tively small, and very few study participants withdrew over 
Table 4 Biomedical indicators at study end
  
Patients who have 
a single condition 
occurring alone
The condition occurs 
with other conditions, 
causing multimorbidity Both combined
Blood pressure (mm Hg), number (%) n=415 n=469 n=884
  ≥140/90 183 (44.1) 225 (48.0) 408 (46.2)
  <140/90 232 (55.9) 244 (51.2) 476 (53.9)
  ≥180/120 7 (1.7) 25 (5.3) 32 (3.6)
  <180/120 408 (98.3) 444 (94.7) 852 (96.4)
Systolic BP mm Hg, mean (range) 133.9 (26.0–228) 136.7 (90.0–227) 135.4 (26–228)
Diastolic BP mm Hg, mean (range) 83.9 (53–130) 85.6 (44–185) 84.8 (44–185)
Fasting glucose (mmol/L), number (%) n=189 n=242 n=431
  <6.1 36 (19.1) 69 (28.5) 105 (24.4)
  6.1–6.9 28 (14.8) 33 (13.6) 61 (14.2)
  ≥7.0 125 (66.1) 140 (57.9) 265 (61.5)
Fasting glucose, mean (range) mmol/L 9.7 (3.6–28.5) 8.3 (3.6–19.8) 8.9 (3.6–28.5)
HbA1c, number (%). n=84 n=140 n=224
  <6% 17 (20.2) 31 (22.1) 48 (21.4)
  6.0%–6.4% 4 (4.8) 15 (10.7) 19 (8.5)
  ≥6.5% 63 (75.0) 94 (67.1) 157 (70.1)
HbA1c, mean (range) percent 7.6 (0.6–13.5) 7.3 (0.6–15.9) 7.4 (0.6–15.9)
HIV plasma viral load, number (%)* n=322 n=156 n=478
  <100 copies/mL 278 (86.3) 145 (93.0) 423 (88.5)
  100–999 copies/mL 27 (8.4) 9 (5.8) 36 (7.5)
  ≥1000 copies/mL 17 (5.3) 2 (1.3) 19 (4.0)
Note: 80 persons were newly diagnosed with second or third conditions over the course of the follow- up (see table 3). Their final follow- up 
indicators are not included in the analyses above as these patients may have been newly started on treatment and therefore will not have had 
time to stabilise.
*The 95% CI for plasma viral load <100 copies/mL for both groups combined was 85.7, 91.4%. The proportion with plasma viral load <1000 
copies/mL was 96.0% (95% CI: 94.3% to 97.8%).
BP, blood pressure; HbA1c, glycated haemoglobin.
Table 5 Risk differences (95% CI) between baseline and study end among participants living with hypertension, diabetes or 
HIV infection
Clinical condition (either alone or alongside 
other conditions) All participants
Excluding participants in care for 
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time. HIV has a special status in almost all African coun-
tries, which may have contributed to the stigma associated 
with this disease. Our study suggests that HIV infection 
can be managed in the same space as other conditions—
that is, that HIV can be considered like any other disease 
or condition—and this will not make a difference to the 
outcome for the patient living with HIV infection.
Although we achieved high rates of retention, and 
blood pressure and glycaemia control improved over 
time, a high percentage of those with diabetes or hyper-
tension continued to have uncontrolled blood pressure 
and uncontrolled glycaemia at the end of the study, in 
contrast to the situation with HIV for which the vast 
majority maintained excellent control of viraemia. In the 
case of diabetes, this is complicated by a lack of access 
to adequate monitoring. Access to HbA1c testing was a 
challenge we faced in this study, and is a challenge across 
Africa.32 The next step in this story is to identify and test 
interventions that improve blood pressure and diabetes 
control (among people in care) and take this control 
to levels achieved by HIV programmes in order to drive 
down mortality from non- communicable diseases.
Large numbers of people in high- income countries 
are now living with multiple conditions—so called multi-
morbidity—and this number is expected to continue to 
rise sharply in Africa, if it has not done so. In our study, 
individuals with more than one condition, who would 
normally attend multiple different clinics, appeared to 
have a higher retention in care than people with a single 
condition but their clinical indicators at study end were 
no different from those with a single condition. While it 
is not surprising that their retention should be high, the 
lack of superiority in their clinical indicators from those 
with a single condition suggest that greater efforts will be 
needed to improve clinical outcomes.
Studies that involve reorganisation of care provision 
represent huge change and challenges for health services, 
communities and patients. They are not possible without 
partnerships based on an ethos of equality and openness 
and without the building of trust between researchers 
and these stakeholders. It is essential that research of this 
nature allows time and resource for the working together 
of different groups of researchers, healthcare providers 
and public health authorities, patients and communities.
Strengths and limitations
Although the evidence generated by our study is much 
greater than that available to most policymakers, and sepa-
rate clinics for each chronic condition are not sustainable 
for Ministries of Health, changes to health policy that 
would affect tens of millions of people living with chronic 
conditions requires robust evidence. Our study was large, 
comprising over 2000 participants with different chronic 
conditions. However, it was a pilot study and did not 
have a comparison group. It was done in just 10 health 
facilities, 5 in Tanzania and 5 in Uganda. In some health 
facilities, the number of people presenting with HIV or 
hypertension was high and the facilities had no system for 
recording the order in which patients presented and so 
we were unable to choose participants systematically but 
selected them purposively. This could have introduced 
selection bias.
Evidence is needed from large randomised trials 
with control groups comprising current standard care 
as provided in stand- alone clinics,17 with replication in 
multiple settings and over a longer duration of follow- up 
and with systematic or random sampling of participants 
to reduce the possibility bias. We also need more evidence 
on why integrated care works for different groups of 
people either with single or with multiple conditions.
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